Reports by Industry
Reports by Company
- Company Analysis(173)
- Company Profile(60)
Point of Care Diagnostics to Chip in 34% in Global IVD Market
Jun 17, 2008
The leading market research firm RNCOS has launched its new report, “Global In Vitro Diagnostic Market Analysis”, that anticipates the worldwide In Vitro Diagnostic (IVD) market to hit the total revenues of about US$ 53 Billion by 2012. Out of this, Point of Care Diagnostics (POCT) currently makes up for the largest share in the global IVD market and is projected to maintain its share during the forecasted period.
POCT is real-time diagnostic testing which is performed near to or at the patient’s site with the result may leading to a change in the patient’s treatment.
According to the RNCOS research, POCT is one of the fastest growing and biggest segments of the IVD market. The segment accounted for around 33.4% of the total market in 2007. The POCT segment is forecasted to gain more popularity in future due to the multitude of benefits its offers, including faster results, availability of new computer systems and biosensor technologies, rising adoption of self-testing products, and improving demand for more efficient testing methods by physicians.
As a result, revenues from the POCT market are forecasted to register CAGR growth of nearly 6.9%, higher than the overall market’s growth (in CAGR terms) of around 6.7%. Blood glucose testing, which contributed 70% share in the POCT market, is likely to remain the largest segment in future, while cardiac markers with 3% share are expected to emerge as the fastest growing one.
“Global In Vitro Diagnostic Market Analysis” provides comprehensive and detailed overview on the global IVD market with thorough analysis on traditional IVD market, new emerging technologies, market size, growth, share, geographical distribution, segmentation, growth factors, trends and challenges for the development of the market. The report also gives forecast on regional IVD market, segment-wise (clinical segment) IVD market, like molecular diagnostics, immune chemistry, clinical chemistry, microbiology and blood screen immunoassays.
For more information visit: http://www.rncos.com/Report/IM103.htm
Some of our Related Reports are as follows:Â
Related Releases are as follows:
- Green Go to Derma Clinical Trial - How will it Shape Industry?
- Liquid Biopsy Paving the Way to Growth through Strategic Transactions
- India- A Largely Untapped Market for NIPT
- Government Initiatives Promoting the Indian Healthcare Sector
- Clinical Chemistry Testing Major Driver for US Clinical Laboratory Testing Market
Media Citation
- testtest
19 Jan, 2024 - Yourstory.com News @ Foodtech startup Swiggy launches Health Hub in Chennai
23 Mar, 2021 - Yourstory.com News @ Zomato forays into dietary supplements, makes its own 'made in India' brand
16 Mar, 2021 - View more
get in touch
Copyright © 2014, RNCOS, 2002-2014
About Us
Terms & Policy
Contact